85 related articles for article (PubMed ID: 26346843)
1. Risk factors: Immune tolerance confers cancer risk.
Sidaway P
Nat Rev Clin Oncol; 2015 Oct; 12(10):564. PubMed ID: 26346843
[No Abstract] [Full Text] [Related]
2. Treg-Mediated Immune Tolerance and the Risk of Solid Cancers: Findings From EPIC-Heidelberg.
Barth SD; Schulze JJ; Kühn T; Raschke E; Hüsing A; Johnson T; Kaaks R; Olek S
J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26298011
[TBL] [Abstract][Full Text] [Related]
3. Immunology. Guilty by association.
Joshi NS; Jacks T
Science; 2013 Mar; 339(6124):1160-1. PubMed ID: 23471395
[No Abstract] [Full Text] [Related]
4. Re: Aire-dependent thymic development of tumor-associated regulatory T cells.
Atala A
J Urol; 2013 Nov; 190(5):1954. PubMed ID: 24120816
[No Abstract] [Full Text] [Related]
5. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway.
Peng G; Wang HY; Peng W; Kiniwa Y; Seo KH; Wang RF
Immunity; 2007 Aug; 27(2):334-48. PubMed ID: 17656116
[TBL] [Abstract][Full Text] [Related]
6. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
7. Neuroimmunomodulation in cancer patients: correlations between melatonin and beta-endorphin blood levels and T helper/suppressor ratio.
Barni S; Lissoni P; Crispino S; Cattaneo G; Rovelli F; Fumagalli G; Tancini G
Int J Biol Markers; 1988; 3(2):82-6. PubMed ID: 2977397
[TBL] [Abstract][Full Text] [Related]
8. Nonspecific suppressor cells in peripheral blood of patients with urologic cancers.
Herr HW
Surg Forum; 1978; 29():623-5. PubMed ID: 162612
[No Abstract] [Full Text] [Related]
9. The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns.
Türbachova I; Schwachula T; Vasconcelos I; Mustea A; Baldinger T; Jones KA; Bujard H; Olek A; Olek K; Gellhaus K; Braicu I; Könsgen D; Fryer C; Ravot E; Hellwag A; Westerfeld N; Gruss OJ; Meissner M; Hasan MT; Weber M; Hoffmüller U; Zimmermann S; Loddenkemper C; Mahner S; Babel N; Berns E; Adams R; Zeilinger R; Baron U; Vergote I; Maughan T; Marme F; Dickhaus T; Sehouli J; Olek S
Epigenetics; 2013 Nov; 8(11):1226-35. PubMed ID: 24071829
[TBL] [Abstract][Full Text] [Related]
10. Acute rejection, T-cell-depleting antibodies, and cancer after transplantation.
Lim WH; Turner RM; Chapman JR; Ma MK; Webster AC; Craig JC; Wong G
Transplantation; 2014 Apr; 97(8):817-25. PubMed ID: 24521777
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of innate immune system function in metastatic breast, colorectal, and prostate cancer patients with circulating tumor cells.
Santos MF; Mannam VK; Craft BS; Puneky LV; Sheehan NT; Lewis RE; Cruse JM
Exp Mol Pathol; 2014 Jun; 96(3):367-74. PubMed ID: 24731923
[TBL] [Abstract][Full Text] [Related]
12. Performance of a rosette assay between lymphocytes and sheep erythrocytes at elevated temperatures to study patients with cancer and other diseases.
West WH; Sienknecht CW; Townes AS; Herberman RB
Clin Immunol Immunopathol; 1976 Jan; 5(1):60-6. PubMed ID: 1261100
[No Abstract] [Full Text] [Related]
13. Immune and endocrine mechanisms of advanced cancer-related hypercortisolemia.
Lissoni P; Brivio F; Fumagalli L; Messina G; Secreto G; Romelli B; Fumagalli G; Rovelli F; Colciago M; Brera G
In Vivo; 2007; 21(4):647-50. PubMed ID: 17708360
[TBL] [Abstract][Full Text] [Related]
14. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J
Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of serum CA 50 levels in cancer using a time-resolved fluoroimmunoassay.
Cooper EH; Knowles JC; Parker D; Taylor M
Biomed Pharmacother; 1988; 42(3):189-96. PubMed ID: 3179405
[TBL] [Abstract][Full Text] [Related]
16. Carcinoembryonic antigen.
Lancet; 1971 Sep; 2(7725):645-6. PubMed ID: 4105952
[No Abstract] [Full Text] [Related]
17. Indicators of Cellular and Developmental Disorders in Multiple Primary Cancers.
Redzović A; Dintinjana RD; Nacinović AD
Coll Antropol; 2016 Apr; 40(1):59-62. PubMed ID: 27301239
[TBL] [Abstract][Full Text] [Related]
18. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells.
Degl'Innocenti E; Grioni M; Capuano G; Jachetti E; Freschi M; Bertilaccio MT; Hess-Michelini R; Doglioni C; Bellone M
Cancer Res; 2008 Jan; 68(1):292-300. PubMed ID: 18172322
[TBL] [Abstract][Full Text] [Related]
19. [Carcinoembryonic antigen in oncology].
Tkacheva GA
Med Radiol (Mosk); 1983 Aug; 28(8):69-76. PubMed ID: 6310310
[No Abstract] [Full Text] [Related]
20. Increase of regulatory T cells in the peripheral blood of cancer patients.
Wolf AM; Wolf D; Steurer M; Gastl G; Gunsilius E; Grubeck-Loebenstein B
Clin Cancer Res; 2003 Feb; 9(2):606-12. PubMed ID: 12576425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
